Treatment of multiple sclerosis with natalizumab: experiences from a real-life cohort over 15 years

被引：0
|
作者：
Auer, M. [1 ]
Zinganell, A. [1 ]
Hegen, H. [1 ]
Bsteh, G. [2 ]
Di Pauli, F. [1 ]
Berek, K. [1 ]
Fava, E. [1 ]
Wurth, S. [3 ]
Berger, T. [2 ]
Deisenhammer, F. [1 ]
机构：
[1] Med Univ Innsbruck, Innsbruck, Austria
[2] Med Univ Vienna, Vienna, Austria
[3] Med Univ Graz, Graz, Austria
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P693
引用
下载
收藏
页码：588 / 588
页数：1
相关论文
共 50 条
  • [1] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Auer, Michael
    Zinganell, Anne
    Hegen, Harald
    Bsteh, Gabriel
    Di Pauli, Franziska
    Berek, Klaus
    Fava, Elena
    Wurth, Sebastian
    Berger, Thomas
    Deisenhammer, Florian
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [2] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Michael Auer
    Anne Zinganell
    Harald Hegen
    Gabriel Bsteh
    Franziska Di Pauli
    Klaus Berek
    Elena Fava
    Sebastian Wurth
    Thomas Berger
    Florian Deisenhammer
    Scientific Reports, 11
  • [3] Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort
    Kallweit, Ulf
    Jelcic, Ilijas
    Braun, Nathalie
    Fischer, Heike
    Zoerner, Bjoern
    Schreiner, Bettina
    Sokolov, Arseny A.
    Martin, Roland
    Weller, Michael
    Linnebank, Michael
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (02) : 77 - 80
  • [4] Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort
    Kallweit, U.
    Jelcic, I.
    Braun, N.
    Fischer, H.
    Zoerner, B.
    Schreiner, B.
    Sokolov, A.
    Martin, R.
    Weller, M.
    Linnebank, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S429 - S429
  • [5] Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis
    Jessica Frau
    Giancarlo Coghe
    Lorena Lorefice
    Giuseppe Fenu
    Luigina Musu
    Eleonora Cocco
    Journal of Neurology, 2019, 266 : 1405 - 1411
  • [6] Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis
    Frau, Jessica
    Coghe, Giancarlo
    Lorefice, Lorena
    Fenu, Giuseppe
    Musu, Luigina
    Cocco, Eleonora
    JOURNAL OF NEUROLOGY, 2019, 266 (06) : 1405 - 1411
  • [7] REAL-LIFE EFFECTIVENESS OF NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): A REGISTRY ANALYSIS
    Danko, D.
    Manca, A.
    Mor, Z.
    Csepany, T.
    VALUE IN HEALTH, 2014, 17 (03) : A56 - A57
  • [8] Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2019, 266 (11) : 2672 - 2677
  • [9] Real-life outcomes of Ocrelizumab treatment from 3 multiple sclerosis centers in Turkey
    Vural, E.
    Terzi, M.
    Sunter, G.
    Gunal, D.
    Agan, K.
    Boz, C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 751 - 751
  • [10] Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey
    Terzi, M.
    Kurtuncu, M.
    Eraksoy, M.
    Karabudak, R.
    Tuncer, A.
    Altunrende, B.
    Akcali, A.
    Boz, C.
    Sevim, S.
    Nur, Y.
    Tamam, Y.
    Bitnel, M.
    Turan, O. F.
    Soysal, A.
    Ozerden, M.
    Terzi, Y.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 310 - 310
12345